Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsFACCT Trial, 2021 0.69 [0.28; 1.68] GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Krolewiecki, 2020 0.49 [0.01; 26.05] Silva, 2021 0.46 [0.03; 8.02] 0.56[0.31; 1.00]FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Krolewiecki, 2020, Silva, 202160%1,613moderatenot evaluable deathsdetailed resultsAbd-Elsalam, 2021 0.74 [0.16; 3.42] ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44] Dabbous HM, 2020 0.51 [0.02; 15.41] FACCT Trial, 2021 0.96 [0.44; 2.08] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Khamis, 2020 0.83 [0.23; 2.96] Kirti, 2021 0.12 [0.01; 2.36] Krolewiecki, 2020 0.49 [0.01; 26.05] NCT04342650, 2020 0.95 [0.02; 48.42] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] NCT04542694, 2020 1.00 [0.02; 50.90] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Rocco, 2020 1.02 [0.02; 51.70] Shenoy S, 2021 1.32 [0.58; 2.99] Udwadia, 2020 0.50 [0.02; 15.03] Zhaowei Chen, 2020 1.00 [0.02; 52.04] 0.77[0.55; 1.09]Abd-Elsalam, 2021, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Dabbous HM, 2020, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Krolewiecki, 2020, NCT04342650, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Shenoy S, 2021, Udwadia, 2020, Zhaowei Chen, 2020220%4,941moderatecritical deaths (time to event analysis only)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] 0.64[0.28; 1.48]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,141moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] ELACOI (Standard of care), 2020 0.86 [0.06; 11.36] I-TECH (Lim), 2022 1.25 [0.87; 1.80] Kamran, 2020 0.95 [0.32; 2.78] Li T, 2020 0.48 [0.01; 27.44] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95] Rocco, 2020 1.02 [0.29; 3.58] Zhaowei Chen, 2020 0.11 [0.01; 2.19] 0.94[0.70; 1.26]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, I-TECH (Lim), 2022, Kamran, 2020, Li T, 2020, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Zhaowei Chen, 20201120%2,777moderatelow clinical improvementdetailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Chachar, 2020 1.19 [0.38; 3.72] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] NCT04542694, 2020 2.10 [1.04; 4.24] Rocco, 2020 0.81 [0.52; 1.27] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Tang, 2020 1.01 [0.59; 1.74] Udwadia, 2020 1.75 [1.10; 2.79] 1.23[1.00; 1.53]AVIFAVIR, 2020, Chachar, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Rocco, 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 20201250%3,110moderatelow clinical improvement (14-day)detailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] Ruzhentsova T, 2020 1.28 [1.05; 1.56] 1.19[0.97; 1.46]AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020728%2,235moderatenot evaluable clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable clinical improvement (28-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] Ruzhentsova T, 2020 1.11 [0.96; 1.29] Udwadia, 2020 1.75 [1.10; 2.79] 1.47[1.06; 2.04]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020459%1,102moderatenot evaluable clinical improvement (7-day)detailed resultsChachar, 2020 1.19 [0.38; 3.72] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] Kirti, 2021 0.90 [0.77; 1.06] NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] NCT04542694, 2020 2.10 [1.04; 4.24] Rocco, 2020 0.81 [0.52; 1.27] Ruzhentsova T, 2020 1.50 [1.02; 2.21] 1.19[0.95; 1.49]Chachar, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Rocco, 2020, Ruzhentsova T, 2020965%2,400moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Shenoy S, 2021 0.99 [0.77; 1.28] Shinkai, 2021 1.40 [0.91; 2.15] Tang, 2020 1.01 [0.59; 1.74] Udwadia, 2020 1.75 [1.10; 2.79] 1.21[1.03; 1.41]FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Shenoy S, 2021, Shinkai, 2021, Tang, 2020, Udwadia, 2020948%2,823moderatenot evaluable hospital dischargedetailed resultsFACCT Trial, 2021 0.88 [0.64; 1.21] Kirti, 2021 1.20 [0.73; 1.98] Li T, 2020 10.00 [1.03; 97.50] RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04] Shenoy S, 2021 1.06 [0.85; 1.32] Udwadia, 2020 1.41 [0.97; 2.03] 1.16[0.91; 1.48]FACCT Trial, 2021, Kirti, 2021, Li T, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shenoy S, 2021, Udwadia, 2020643%1,439moderateserious hospitalizationdetailed resultsHolubar M, 2021 0.12 [0.01; 2.26] 0.12[0.01; 2.26]Holubar M, 202110%149NAnot evaluable mechanical ventilationdetailed resultsAbd-Elsalam, 2021 1.00 [0.20; 5.11] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37] GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] I-TECH (Lim), 2022 0.41 [0.13; 1.30] Kirti, 2021 0.20 [0.00; 8.69] Li T, 2020 0.40 [0.04; 3.90] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Udwadia, 2020 0.06 [0.01; 0.83] 0.68[0.35; 1.32]Abd-Elsalam, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Kirti, 2021, Li T, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Udwadia, 20201039%2,410moderatecritical mechanical ventilation (time to event analysis only)detailed resultsUdwadia, 2020 0.06 [0.01; 0.83] 0.06[0.01; 0.83]Udwadia, 202010%14NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] ELACOI (Standard of care), 2020 0.18 [0.01; 3.99] Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88] 1.17[0.42; 3.26]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad A (AZI vs SoC), 2021316%252moderatenot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] ELACOI (Standard of care), 2020 0.08 [0.00; 1.71] Zhaowei Chen, 2020 3.43 [1.10; 10.70] 0.40[0.02; 6.97]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Zhaowei Chen, 2020377%108moderatenot evaluable viral clearance detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Chaccour, 2020 0.92 [0.77; 1.09] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] Holubar M, 2021 0.76 [0.48; 1.20] NCT04542694, 2020 13.03 [2.96; 57.24] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Tang, 2020 0.85 [0.58; 1.23] Udwadia, 2020 1.37 [0.94; 1.98] 1.18[0.91; 1.53]AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, NCT04542694, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 20201258%1,195moderatecritical viral clearance (time to event analysis only)detailed resultsAhmed, 2020 4.10 [1.12; 14.99] Holubar M, 2021 0.76 [0.48; 1.20] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Tang, 2020 0.85 [0.58; 1.23] Udwadia, 2020 1.37 [0.94; 1.98] 1.12[0.81; 1.56]Ahmed, 2020, Holubar M, 2021, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020562%689moderatenot evaluable viral clearance by day 14detailed resultsAhmed, 2020 4.10 [1.12; 14.99] AVIFAVIR, 2020 3.08 [0.62; 15.39] Bukhari, 2021 0.91 [0.02; 46.94] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Li T, 2020 1.00 [0.03; 34.67] Ruzhentsova T, 2020 0.99 [0.93; 1.06] 1.42[0.84; 2.40]Ahmed, 2020, AVIFAVIR, 2020, Bukhari, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Ruzhentsova T, 2020719%455moderateserious viral clearance by day 7detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Bukhari, 2021 11.56 [3.53; 37.91] Chaccour, 2020 0.92 [0.77; 1.09] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] ELACOI (Standard of care), 2020 0.67 [0.10; 4.58] Kirti, 2021 0.80 [0.43; 1.50] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] Ruzhentsova T, 2020 1.05 [0.92; 1.20] 1.18[0.87; 1.61]AVIFAVIR, 2020, Bukhari, 2021, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020969%714moderatenot evaluable ICU admissiondetailed resultsFACCT Trial, 2021 1.42 [0.79; 2.55] I-TECH (Lim), 2022 0.78 [0.27; 2.23] Khamis, 2020 1.03 [0.35; 3.03] Kirti, 2021 0.90 [0.30; 2.70] Rocco, 2020 4.11 [0.18; 91.83] 1.17[0.77; 1.78]FACCT Trial, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Rocco, 202050%1,337moderatenot evaluable recoverydetailed resultsGS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.15[0.99; 1.33]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable serious adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10] GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] Krolewiecki, 2020 1.00 [0.03; 31.59] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] NCT04542694, 2020 6.15 [0.30; 124.49] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Ruzhentsova T, 2020 2.06 [0.09; 46.40] Shinkai, 2021 2.80 [0.14; 56.95] Udwadia, 2020 1.03 [0.02; 52.48] 0.76[0.47; 1.22]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020110%2,865moderatecritical acute kidney injury detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18] 1.18[0.44; 3.18]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78] GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01] Holubar M, 2021 2.07 [0.89; 4.83] Krolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] NCT04542694, 2020 1.00 [0.54; 1.85] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47] Ruzhentsova T, 2020 1.90 [0.96; 3.80] Shinkai, 2021 19.54 [7.77; 49.11] Udwadia, 2020 6.36 [2.43; 16.65] 1.98[1.39; 2.82]Chaccour, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 20201670%3,427moderatelow arrhythmiadetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69] 2.24[0.23; 21.69]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable elevated liver enzymesdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64] 3.48[1.40; 8.64]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable long QTdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50] 9.79[1.27; 75.50]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%174NAnot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86] 1.35[0.47; 3.86]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable Thromboembolic eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55] 0.89[0.31; 2.55]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-04-16 12:29 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons